21 Dec 2020 – Destiny Pharma joins the Pharmabiotic Research Institute (PRI)

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Destiny Pharma joins the Pharmabiotic Research Institute (PRI)

Brighton, United Kingdom – 21 December 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, has become a member of the Pharmabiotic Research Institute (PRI).

Destiny Pharma has added two active biotherapeutic programs to its pipeline in 2020; a Phase 3 clinical program targeting C.difficile infection recurrence and a grant funded pre-clinical collaboration with SporeGen Limited for the prevention of COVID-19 and other viral respiratory infections. Destiny Pharma is therefore now very active in  biotherapeutic/microbiome product development.

PRI is focused on the human microbiome and is a neutral, non-profit association that applies a collaborative approach to identify and confirm the specific Scientific and Regulatory requirements of microbiome-based, medicinal products, developed for the European market. The PRI counts more than 80 relevant stakeholders from the microbiome and human health field and is the leading centre for microbiome regulatory science.

The global human microbiome market is expected to reach US$1.9 billion by 2027 driven by factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies, and growing technological advancements in metagenomics and next-generation sequencing.

Neil Clark, Chief Executive Officer of Destiny Pharma, said: “We are very pleased to have joined the Pharmabiotic Research Institute.  We look forward to collaborating with PRI and their members with the combined goal of enhancing the development of a European regulatory framework for microbiome products and usiing this insight to assist us in the development of our two biotherapeutic products targeting C. difficile infection recurrence and COVID-19. As a member of PRI, Destiny Pharma will learn about best practice and contribute to regulatory developments in this fast-growing microbiome sector”.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit https://www.destinypharma.com

About the Pharmabiotic Research Institute (PRI)
The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 to support the development of microbiome-based medicines for the EU market, for the ultimate benefit of patients. It applies a unique ‘Share & Learn’ approach to overcome the complex and various regulatory challenges faced by relevant stakeholders. Its overall mission is to facilitate the conversation between European regulators and Microbiome medicinal product developers and their partners, and to become the key network of stakeholders driving the new therapeutic and diagnostic innovation in the field microbiome science. For further information, please visit https://www.pharmabiotic.org